{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014477","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.192808+00:00","generated_at":"2026-06-24T04:26:40.340134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials","bullets":["Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.","Cash, equivalents and marketable securities $291.8M as of June 30, 2022, expected to fund operations into H2 2024.","FDA lifted clinical hold on DYNE-251 IND for Phase 1/2 MAD trial in DMD patients amenable to exon 51 skipping; dosing expected mid-2022.","New Zealand cleared clinical trial application for DYNE-101 Phase 1/2 MAD trial in DM1; patient dosing expected mid-2022.","Presented preclinical data for DYNE-101 at ASGCT showing robust DMPK RNA knockdown in muscle models."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014477","json":"https://secwatch.observer/filing/0000950170-22-014477.json","markdown":"https://secwatch.observer/filing/0000950170-22-014477.md","text":"https://secwatch.observer/filing/0000950170-22-014477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/0000950170-22-014477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/dyn-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:26:40.340134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}